Overview

Gender

male

Investor Type

Investment Partner

Andrew has more than 10 years experience as an analyst in the pharmaceutical and biotechnology sectors. He joined Abingworth in 2008 from HSBC Global Markets, where he was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at Credit Suisse and SG Cowen. He completed a PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Andrew qualified as a chartered accountant with KPMG. At Abingworth, he evaluates opportunities in public companies and is a fund manager for open market transactions.